Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 4/20 | 0.34 |
| ▸ | PFKFB4 | Q16877 | 8/20 | 0.33 |
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 2/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483443 | 0.92 | PFKFB3 (0.33) | CMA1PFKFB4PFKFB3HTR6NPSR1 | |
| SCHEMBL3483436 | 0.92 | PFKFB3 (0.33) | CMA1PFKFB4PFKFB3HTR6NPSR1 | |
| Hydrochloric Acid SCHEMBL3483805 | 0.91 | PFKFB3 (0.32) | CMA1PFKFB4PFKFB3HTR6NPSR1 | |
| Hydrochloric Acid SCHEMBL3483803 | 0.91 | PFKFB3 (0.32) | CMA1PFKFB4PFKFB3HTR6NPSR1 | |
| SCHEMBL3484384 | 0.85 | PFKFB4 (0.38) | CMA1PFKFB4PFKFB3HTR6NPSR1 | |
| SCHEMBL3483847 | 0.83 | CMA1 (0.41) | CMA1PFKFB4PFKFB3NPSR1L3MBTL1 | |
| SCHEMBL3483422 | 0.82 | PFKFB3 (0.32) | PFKFB4PFKFB3HTR6DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL3483529 | 0.81 | PFKFB3 (0.31) | PFKFB4PFKFB3 | |
| SCHEMBL3483808 | 0.80 | HTR2A (0.32) | CMA1PFKFB4PFKFB3HTR6DRD2 | |
| Trifluoroacetic Acid SCHEMBL3483511 | 0.79 | CA12 (0.37) | CMA1PFKFB4PFKFB3PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | claimed |
| EP-2049200-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MethylGene Inc. (CA) | 2009-04-22 | — | — | EP | claimed |
| WO-2008073142-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | CMA1 356/4885PFKFB4 577/4885PFKFB3 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.